Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course.
Cancers (Basel)
; 13(23)2021 Dec 04.
Article
in En
| MEDLINE
| ID: mdl-34885231
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Cancers (Basel)
Year:
2021
Document type:
Article
Affiliation country:
Alemania
Country of publication:
Suiza